Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

"N of 1" Research: Molecular Findings Create Urgency for New Drug Discovery Paradigm

January 13th 2014

There has been considerable discussion within the oncology literature during the past several years regarding the level of evidence required to consider a new antineoplastic agent an acceptable "standard-of-care" in routine disease management.

Final Thoughts on Clinical Advances in MDS and CML

January 9th 2014

Oral Azacitidine and Lenalidomide Combinations in MDS

January 9th 2014

Novel Agents and Treatment Strategies in MDS

January 9th 2014

Current and Future Treatment Landscape for MDS

January 9th 2014

Treatment of MDS Refractory to Hypomethylating Agent

January 9th 2014

Defining and Predicting Response to HMAs in MDS

January 9th 2014

Role of Genetic Testing in Myelodysplastic Syndromes

January 9th 2014

Hypomethylating Agents in the Treatment of High-Risk MDS

January 9th 2014

Treatment Selection for Resistant or Intolerant CML

January 9th 2014

Second-Generation Tyrosine Kinase Inhibitors in CML

January 9th 2014

Frontline Treatment of Chronic Myelogenous Leukemia

January 9th 2014

Discontinuation of Treatment With TKIs in CML

January 9th 2014

Introduction: Treatment Landscape of MDS

January 9th 2014

Jerry Lanchbury, PhD, Describes Myriad's HRD Test

January 3rd 2014

Jerry Lanchbury, PhD, Chief Scientific Officer, Myriad Genetics, Inc., describes the HRD (homologous recombination deficiency) test.

Personalized Medicine Takes Another Step Forward

January 3rd 2014

Like you, I get up every day and look at the stack of journals I know I need to read but cannot imagine when I will find the time.

Companion Diagnostics Are Driving Support in the Evolving Regulatory Landscape

December 30th 2013

Owing to the high clinical failure rates, genetically variable tumor characteristics, and skyrocketing drug development costs, the era of traditional blockbuster oncology agents has come to an end.

PI3K-Targeting Agents May Help Overcome Resistance in Breast Cancer Treatment

December 20th 2013

Through a variety of research roles, Sara Hurvitz, MD, is exploring novel targeted therapies for the treatment of breast cancer, including developing and implementing clinical trials. Her interests include the phosphatidylinositol 3-kinase (PI3K) signaling pathway.

Targeting PI3K: A New Generation of Agents Emerges

December 5th 2013

The phosphatidylinositol 3-kinase pathway is frequently deregulated in cancer at multiple different points, and has therefore emerged as one of the most deeply explored cell-signaling networks in oncogenic research.

Dr. Finn on AMG900 in Breast Cancer

December 2nd 2013

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses using AMG900 to treat breast cancer.

x